These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25816840)

  • 1. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.
    Staiger AM; Ott MM; Parmentier S; Rosenwald A; Ott G; Horn H; Griese EU
    Br J Haematol; 2015 Oct; 171(1):145-8. PubMed ID: 25816840
    [No Abstract]   [Full Text] [Related]  

  • 2. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
    JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells.
    Ouk C; Roland L; Gachard N; Poulain S; Oblet C; Rizzo D; Saintamand A; Lemasson Q; Carrion C; Thomas M; Balabanian K; Espéli M; Parrens M; Soubeyran I; Boulin M; Faumont N; Feuillard J; Vincent-Fabert C
    Front Immunol; 2021; 12():641692. PubMed ID: 34017329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
    Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
    Shi H; Zhou X; Chen B; Xiao J; Li Y; Zhou X; Zhou Q; Chen K; Wang Q
    Ocul Immunol Inflamm; 2021 Apr; 29(3):448-455. PubMed ID: 31603365
    [No Abstract]   [Full Text] [Related]  

  • 10. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
    Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
    Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
    Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
    Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
    Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
    Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
    Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma.
    Pulido JS; Salomao DR; Frederick LA; Viswanatha DS
    Retina; 2015 Apr; 35(4):624-7. PubMed ID: 25768255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.
    Raja H; Salomão DR; Viswanatha DS; Pulido JS
    Retina; 2016 Mar; 36(3):624-8. PubMed ID: 26900675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
    Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
    Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
    Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
    Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
    Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.